Effect of inhaled airway widening medication on exhaled nitric oxide (an airway inflammation marker) in chronic obstructive pulmonary disease

Effect of inhaled beta-2-agonist salbutamol on exhaled nitric oxide in chronic obstructive pulmonary disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12616000140459

Enrollment

Registered

2016-02-05

Start date

2014-12-15

Completion date

2015-01-20

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Exhaled nitric oxide (FENO) is a marker of airway inflammation, and high levels are associated with greater responsiveness of airways disease to steroid treatment. Studies have shown that, in the presence of narrowed airways in asthma, FENO levels can be reduced, but the effects in smoking related chronic obstructive lung disease (COPD) are unknown. This is important as we may be underestimating FENO levels in COPD patients who might otherwise benefit from steroid therapy. We aim to perform FENO measurements in twenty COPD patients before and after bronchodilator (reliever) therapy, to test the hypothesis that FENO increases with wider airway calibre.

Interventions

Observation of exhaled nitric oxide immediately before and then 15 minutes after 400 micrograms of inhaled salbutamol (4 puffs of participants' usual reliever medication). Exhaled nitric oxide measurement required participants to blow out through a tube at a constant flow rate using visual feedback from a computer screen giving a target flow rate. Exhaled nitric oxide measurements were performed immediately before and then 15 minutes after the dose of inhaled salbutamol with no further follow-

Eligibility

Sex/Gender

All

Age

45 Years to No maximum

Healthy volunteers

Inclusion criteria

Diagnosis of chronic obstructive pulmonary disease, aged 45 years or older, smoking history of more than 10 pack years, taking inhaled salbutamol as required, post-bronchodilator FEV1/FVC of less than 70% and FEV1 < 80% predicted.

Exclusion criteria

No exacerbations or use of antibiotics in the two weeks preceding study participation. No patients with diagnosed lung cancer, bronchiectasis, or other significant co-morbidity. No patients unable to perform the 50mL/s exhaled nitric oxide manoeuvres in accordance with American Thoracic Society guidelines

Outcome results